key: cord-0037125-fd6hfwki
authors: Kroll, Michael H.
title: Hematology
date: 2015-04-13
journal: Approach to Internal Medicine
DOI: 10.1007/978-3-319-11821-5_6
sha: 1594ab9432bf4cd3b4c829ee9764dd16a1466568
doc_id: 37125
cord_uid: fd6hfwki

—stress (Gaisböck’s syndrome), decreased intravascular volume

TREAT UNDERLYING CAUSErelative (hydration), CO hemoglobinemia (smoking cessation. See p. 480), sleep apnea (CPAP. See p. 20) , polycythemia vera (cytoreduction with hydroxyurea is preferable to phlebotomy target to keep hematocrit <0.45 in ♂ and <0.42 in ♀, ASA 81 mg PO daily prevents thrombosis-but watch out for bleeding)

NEJM 2005 

HISTORY -shortness of breath, chest pain, dizziness, fatigue, bleeding (GI, menstrual), pica (ice, dirt), diet history, fever, night sweats, weight loss, past medical history (malignancy, chronic infections, rheumatologic disorders), medications (NSAIDs, ASA, anticoagulants), family history (thalassemia) PHYSICAL -vitals, koilonychia (spoon nails), alopecia, blue sclerae, conjunctival pallor, angular cheilitis, atrophic glossitis, lymphadenopathy (anemia of chronic disease), rectal examination for occult blood and pelvic examination for blood loss

· RDW -red cells in thalassemia tend to have a narrower distribution than in iron deficiency · MCV -red cells in thalassemia tend to be smaller than in iron deficiency · RBC -RBC high or normal if thalassemia but tend to decrease proportionally to Hb in iron deficiency 

BASIC · LABS -CBCD, peripheral smear, reticulocyte count, serum iron, serum ferritin, TIBC (transferrin), % sat, Hb electrophoresis, fecal occult blood (if suspect GI bleed) SPECIAL · ENDOSCOPY -gastroscopy and/or colonoscopy targeting symptoms in any man or post-menopausal woman with iron deficiency or in anyone with suspected GI bleeding · SOLUBLE TRANSFERRIN RECEPTOR (sTfR)-helps to distinguish between iron deficiency and anemia of chronic disease. Depleted iron stores is associated with increased sTfR levels · BONE MARROW ASPIRATE AND BIOPSY WITH IRON

· THALASSEMIA INDEX -MCV/RBC. Suggests thalassemia if <13 and iron deficiency if >13 · MORPHOLOGY -thalassemia causes microcytic target cells DISTINGUISHING FEATURES BETWEEN IRON DEFICIENCY AND ANEMIA OF CHRONIC DISEASE -ferritin is indicative of marrow iron stores and is key to the diagnosis of iron deficiency anemia as serum iron and TIBC levels may change with other diseases. Ferritin may be elevated as acute phase reactant · < 30 ng / ml -iron deficiency anemia (PPV 92-98%) · 30 -100 ng / ml -combination of anemia of chronic disease and true iron deficiency if (sTfR/log ferritin) > 2. Anemia of chronic disease alone if (sTfR/log ferritin) <1 · 100 ng / ml -anemia of chronic disease causing agglutination in the laboratory specimen before blood is run through the analyzer COOMBS TEST · DIRECT COOMBS TEST (DAT)-patient's washed RBC incubated with anti-IgG and anti-C3. A positive result (i.e. agglutination) indicates that IgG and/or C3 have bound to RBC surface in vivo. DAT positivity suggests immune rather than nonimmune causes of hemolysis · IMMUNE HEMOLYTIC ANEMIA (DAT positive)autoimmune hemolytic anemia, druginduced hemolytic anemia, alloimmune hemolytic anemia (acute hemolytic reaction) · NON -IMMUNE HEMOLYTIC ANEMIA (DAT negative)-TTP/HUS, DIC, hemoglobinopathies, hereditary spherocytosis · INDIRECT C OOMBS TEST -normal RBC incubated with patient's serum. It is mainly used to detect low concentrations of antibodies in a patient's serum prior to blood transfusion RETICULOCYTE PRODUCTION INDEX (RPI, corrected reticulocyte count)-more accurate than raw reticulocyte count to evaluate if bone marrow response to anemia is appropriate or hypoproliferative · RPI = [retic count × (hematocrit in %/45)]/maturation factor · INTERPRETATION -RPI >2% suggests adequate marrow response, < 2% suggests hypoproliferative (i.e. ↓ production) 

★ABCDEFGH PAIN★ A NEMIA · CHRONIC HEMOLYSIS -normo or macrocytic due to reticulocytosis, elevated bilirubin, LDH, low haptoglobin). There may be associated folate/iron deficiency from increased utilization · ACUTE ANEMIA -may be due to splenic sequestration crisis (venoocclusion of spleen leading to RBC pooling), aplastic crisis (transient arrest of erythropoiesis), and hyperhemolytic crisis (sudden onset of severe hemolysis). All of these may be triggered by viral infections such as parvovirus B19 B ONES -bone infarction (pancytopenia), avascular necrosis, fat embolism, orbital compression syndrome C ARDIAC -myocardial infarction (due to increased oxygen demand from cardiac output) Sickle Cell Disease D ERMATOLOGIC -leg ulcers E YES -proliferative retinopathy, retinal artery occlusion, retinal detachment and hemorrhage F AIRLY BAD PAIN -back, chest, extremities and abdomen. May be associated with fever, swelling, tenderness, tachypnea, hypertension, nausea, and vomiting. May be precipitated by weather changes, dehydration, infection, stress, menses and alcohol. Multi-organ failure may develop in severe pain episodes G ENITAL -priapism H EPATOSPLENIC -splenic infarction, acute hepatic ischemia, hepatic or splenic sequestration crisis, iron overload (transfusions) P ULMONARY -restrictive lung disease (chronic interstitial fibrosis), obstructive lung disease, hypoxemia, pulmonary hypertension, fat embolism A NEMIA -remember that sickle cell disease is associated with both acute and chronic anemia I NFECTIONS -sepsis (particularly asplenic patients), meningitis, pneumonia, osteomyelitis (susceptible to Salmonella and gram negative osteomyelitis) N EUROLOGIC -ischemic stroke, intracerebral hemorrhage, septic emboli, spinal cord infarction or compression, vestibular dysfunction, sensory hearing loss, cognitive failure MANAGEMENT ACUTE -ABC, O 2 , IV · VASOOCCLUSIVE PAIN CRISIS -fluids, pain control (morphine, ketorolac) · APLASTIC CRISIS -transfusions. Avoid GCSF · SEQUESTRATION CRISIS -fluids, judicious transfusion if symptomatic anemia to avoid overload if trapped splenic blood re-enters circulation · HEMOLYTIC CRISIS · ACUTE CHEST SYNDROME (chest pain, pulmonary infiltrates, cough, progressive anemia, hypoxemia, with or without fever)-treat precipitating factor, fluids, pain control, transfusions (simple or exchange) · PRIAPISM -hydration, analgesics, transfusions, urology consultation · PREOPERATIVELY -transfuse to Hb 100 g/L [10 g/dL] CHRONIC -interprofessional team, immunizations ( Streptococcus pneumoniae , Haemophilus influenzae , Niesseria meningitidis , hepatitis B virus, and influenza), exchange transfusion (goal HbS < 30%), hydroxyurea (increase levels of fetal Hb, decrease incidence of vasoocclusive pain), folic acid 1 mg PO daily

ASPLENIC PATIENTS -particularly susceptible to encapsulated bacteria ( S. pneumoniae , H. influenzae , and N. meningitidis 

★PAIN★ P RIMARILY ORGAN -SPECIFIC DISORDERS · PULMONARY -interstitial lung disease, AIDSrelated pneumonia, idiopathic eosinophilic pneumonia, drug-induced lung disease · GASTROINTESTINAL -eosinophilic gastroenteritis, eosinophilic esophagitis, primary biliary cirrhosis, primary sclerosing cholangitits · GENITOURINARY -acute interstitial nephritis, acute post-streptococcal glomerulonephritis, eosinophilic cystitis, eosinophilic prostatitis · RHEUMATOLOGIC -eosinophilia-myalgia syndrome and idiopathic eosinophilic synovitis, Churg-Strauss syndrome · DERMATOLOGIC -eosinophilic panniculitis, episodic angioedema with eosinophilia, Kimura disease and angiolymphoid hyperplasia with eosinophilia, eosinophilic fasciitis, eosinophilic cellulitis, eosinophilic pustular folliculitis, recurrent cutaneous necrotizing eosinophilic vasculitis, eosinophilic ulcers of the oral mucosa A LLERGIES · NASAL -allergic rhinitis, asthma, nasal polyposis · MEDICATIONS -cytokine mediated (GM-CSF, IL-2), pulmonary (NSAIDs), gastroenteritis (NSAIDs), interstitial nephritis (penicillins, cephalosporins), necrotizing myocarditis (ranitidine), vasculitis (phenytoin, allopurinol), asymptomatic (ampicillin, penicillins, cephalosporins) A DRENAL -adrenal insufficiency A THEROEMBOLIC -cholesterol emboli I NFECTIONS · PARASITIC -angiostrongyliasis costaricensis, ascariasis, hookworm, strongyloidiasis, trichinosis · FUNGAL -aspergillosis, coccidioidomycosis · OTHERS -chronic TB, scarlet fever, HIV related N EOPLASTIC · HEMATOLOGIC -hypereosinophilic syndrome, Hodgkin's lymphoma, non-Hodgkin's lymphoma, mastocytosis · SOLID TUMOR -large cell carcinoma ( HEPARININDUCED THROMBOCYTOPENIA AND THROMBOSIS HITT · PATHOPHYSIOLOGY -type I (non-immune) happens within 2 days, mild drop in platelets, and return to normal by itself. Type 2 (immune) starts between days 4 and 14 (can present earlier if recent heparin exposure in past 1-3 months). It is usually more severe (platelet drop >50%) and has great clinical significance. Pathogenesis: heparin complexes with PF4 (from platelets) → IgG against heparin-PF4 complex → these megacomplexes bind to platelets and activate them, producing more PF4 → platelet aggregation → thrombosis · CAUSES -heparin, LMWH (much less likely) · CLINICAL FEATURES (type II)-thrombocytopenia, thrombosis, ischemia · TREATMENTS (type II)-stop heparin immediately and treat with danaparoid , lepirudin , or argatroban until platelets return to normal. Begin warfarin when platelets >150 × 10 3 /μL and overlap warfarin with the alternative anticoagulant for 5 days (this reduces risk of venous limb gangrene). Avoid future heparin exposure except during CABG (performed at least 3 months after heparin exposure) IMMUNE THROMBOCYTOPENIA ITP · PATHOPHYSIOLOGY -autoantibodies against platelets → isolated thrombocytopenia · ASSOCIATIONS -neoplasm (CLL, lymphoma), infections (HIV), autoimmune (SLE) · DIAGNOSIS -isolated thrombocytopenia with an otherwise normal CBC and no obvious causes · TREATMENTS -should be started when platelets < 20 × 10 3 /μL. The goal of treatment is to support platelet counts until spontaneous remission occurs · URGENT SUPPORT -given to patients with active bleeding. IVIG 1 g/kg IV daily × 1-2 days, which may increase the platelet count within days and lasts for a few weeks. Methylprednisolone 1 g IV daily × 3 days. Platelet transfusions may also provide temporary support for actively bleeding patients · FIRST LINEprednisone 1-2 mg/kg PO daily until platelet count returns to normal. Platelet recovery occurs within 3 weeks in 2/3 of patients. If platelet count did not increase after 4 weeks of treatment, consider second line therapies · SECOND LINE -rituximab , thrombopoietic agents (romiplostim, eltrombopag) splenectomy . See p. 163 for details on counseling of patients undergoing splenectomy · OTHER OPTIONS -chemotherapy (CVP), danazol. HAART for HIV-associated ITP NEJM 2002 346:13 EVANS SYNDROME -ITP and autoimmune hemolytic anemia DRUGINDUCED IMMUNE THROMBOCYTO PENIA -patients usually present with severe thrombocytopenia (platelets <20 × 10 3 /μL). With the exception of platelet inhibitors, there is usually 5-7 days between initiation of drug therapy and platelet drop if patient is receiving the medication for the first time. Treatment consists of discontinuation of offending (or all) drugs and platelet transfusions as needed NEJM 2007 357:6 

· PATHOPHYSIOLOGY -vWF acts as a linker between platelets and endothelium and also serves as carrier for factor VIII. Thus, vWD deficiency may lead to decrease in factor VIII levels · CLINICAL FEATURES -platelet disorder with bruising, skin or mucosal bleeding, and heavy menstrual cycles for most subtypes, except type IIN which manifests as hemophilia with soft tissue, joint, and urinary bleeding · DIAGNOSIS -Ristocetin cofactor activity (RCo, assesses capacity of plasma vWF to support ristocetin-induced aggregation of control platelets), collagen binding activity (assesses vWF binding to collagen), vWF antigen (non-functional assay that quantifies vWF), vWF multimer assay (agarose gel to determine the size of multimers), ristocetininduced platelet aggregation (assesses vWF binding to platelets in patients' plateletrich plasma) · TREATMENTS -DDAVP 0.3 μg/kg by IV infusion or 300 μg one spray each nasal for type I patients. vWF concentrates containing all vWF multimers may be used for type II and III and for bleeding and surgical management of type 1 patients BERNARDSOULIER SYNDROME -mutation of GPIb/IX (platelet receptor for vWF) GLANZMANN'S THROMBASTHENIA -mutation of GPIIb/IIIa (platelet receptor for fibrinogen) STORAGE POOL DISEASE -defect in releasing platelet granules (especially ADP) SPECIAL · HEPZYME STUDY -to remove heparin from blood samples to distinguish if isolated elevation of PTT is spurious · 50 : 50 MIXING STUDY -to distinguish between factor deficiency vs. inhibitors (factor deficiency corrects with mixing study) · HEMOPHILIA WORKUP -factors VIII, IX, XI Anticoagulation ↓ risk to < 1%/year MECHANICAL HEART VALVE -recurrent arterial embolic risk 4%/year. Warfarin ↓ risk to < 1%/ year. Mitral valve prostheses 2× risk of aortic valve prostheses. INR 2-3 for bileaflet or tilting disc mechanical valves and 2.5-3.5 for caged-ball or caged-disc valves

ANTIPHOSPHOLIPID ANTIBODY SYNDROME APS · PATHOPHYSIOLOGY -antibody against phospholipids or cell surface proteins bound to anionic phospholipids. These include lupus anticoagulants, anticardiolipin antibody (false-positive VDRL), and anti-β2glycoprotein 1 antibody → may lead to hypercoagulable state · CAUSES -primary APS, secondary APS (various rheumatic diseases such as SLE and infections such as HIV and drugs) · CLINICAL FEATURES -venous and arterial thrombosis and rarely hemorrhage affecting the lungs, heart, CNS, GI, kidneys, skin, and eyes. Also recurrent fetal losses (recurrent first trimester or single late term), thrombocytopenia, and livedo reticularis · DIAGNOSIS -clinical criteria include thrombosis (≥1 arterial, venous, or small-vessel thrombosis in any organ) or pregnancy complications (≥1 unexplained deaths of morphologically normal fetus at or after the 10 th week of gestation, ≥1 premature births of morphologically normal neonate at or before the 34 th week of gestation, or ≥3 unexplained consecutive spontaneous abortions before the 10 th week of gestation). Laboratory criteria include anti-cardiolipin or anti-β2-glycoprotein 1 antibodies (IgG or IgM at moderate or high levels on ≥2 occasions at least 6 weeks apart) or the presence of a lupus anticoagulant (≥2 occasions at least 6 weeks apart). Diagnosis requires at least one clinical and one laboratory criterion (sens 70%, spc 98%) · CATASTROPHIC ANTIPHOSPHOLIPID SYNDROMEacute and devastating syndrome with multiple simultaneous vascular occlusions throughout the body, affecting mainly small vessels of kidney, lungs, CNS, heart, and skin. May be associated with DIC, ARDS, cerebral and myocardial microinfarctions. May be precipitated by infections, surgery, and withdrawal of anticoagulation. Treatment consists of a combination of anticoagulation, steroids, plasmapheresis, and/or IVIG. Mortality rate is 50% · TREATMENTS -primary prophylaxis for thrombosis is not indicated in persons with incidentally discovered antiphospholipid antibodies or lupus anticoagulants. 

-alternative diagnosis more or as likely (−2), recent paralysis/paresis/plaster immobilization (+1), recent bedridden >3 days or major surgery <4 weeks (+1), localized tenderness along deep venous system (+1), calf swelling by more than 3 cm at 10 cm below tibial tuberosity (+1), pitting edema greater in symptomatic leg (+1), collateral non-varicose superficial veins (+1), active cancer (+1) However, patients may experience arm swelling, erythema, pain, warmth, development of collateral vessels and fever. Acute PE, post thrombotic syndrome and persistent vascular compromise represent potential complications · DIAGNOSIS -ultrasound (sens 78-100%, spc 86-100%), venogram is gold standard but rarely done · TREATMENTS -if catheter is still needed (e.g. for chemotherapy administration), consider anticoagulation for at least 3 months with catheter in place, followed by prophylactic doses until catheter removed. Note that in serious cases in which the limb may be threatened or if anticoagulation is contraindicated, catheter may need to be removed regardless. If no need for catheter, consider anticoagulation for 3-5 days, then remove catheter, and then anticoagulation for up to 3 months. Primary prophylaxis is not indicated 

WASHED TRANSFUSION PRODUCT (removes almost all serum proteins and most leukocytes)-IgA deficiency, previous anaphylactic transfusion reaction, febrile reactions not prevented by leukocyte reduction, severe urticarial reactions not prevented by the antihistamines LEUKOCYTEDEPLETED TRANSFUSION PRODUCT (removes most leukocytes)-prevention of febrile reactions or TRALI, prevention of HLA alloimmunization (leukemia, aplastic anemia, chronic hemolytic anemia, MDS, MPS), transplant candidates, substitute for CMV-negative blood IRRADIATED TRANSFUSION PRODUCTS (inhibits lymphocyte proliferation and prevents transfusion-associated GVHD)-stem cell transplant recipients, recipients of directed donor transfusions from blood relatives, Hodgkin's lymphoma CMVNEGATIVE TRANSFUSION PRODUCTS (screened)-CMV-negative transplant recipients (solid organ or bone marrow from CMV negative donors), antepartum transfusions for CMVnegative women INVESTIGATIONS BLOOD TESTS -CBCD, peripheral smear, urea, Cr, LDH, indirect bilirubin, serum hemoglobin, Coombs testing, PTT, INR, fibrinogen, blood C&S, send blood product for culture/typing URINE TESTS -urinalysis IMAGING -CXR 

4. Spleen is not usually ballotable unless gross ascites are present, but the kidney is because of its retroperitoneal position 5. The percussion note is dull over the spleen but is usually resonant over the kidney 6. A friction rub may occasionally be heard over the spleen, but never over the kidney because it is too posterior 

One-handed palpation with patient supine 8.2 0.41 Middleton hooking maneuver 6.5 0.16 APPROACH -"given the low sensitivity of the clinical examination, routine examination for splenomegaly cannot definitively rule in or rule out splenomegaly in normal, asymptomatic patients where the prevalence is <10% and additional imaging tests will be required. Rather, the examination for splenomegaly is most useful to rule in the diagnosis of splenomegaly among patients in whom there is a clinical suspicion of at least 10%. The examination should always start with percussion. If no dullness is detected on percussion, there is no need to palpate as the results of palpation will not effectively rule in or rule out splenic enlargement. If the possibility of missing splenic enlargement remains an important clinical concern, then ultrasound or scintigraphy is indicated. In the presence of percussion dullness, palpation should follow. If both tests are positive, the diagnosis of splenomegaly is established (providing the clinical suspicion of splenomegaly was at least 10% before examination). If palpation is negative, diagnostic imaging will be required to confidently rule in or rule out splenomegaly" JAMA 1993 270:18 UPDATE -palpation may have greater accuracy than percussion, especially in lean patients. Examiners should become proficient in one palpation and one percussion method, because the combination of both results may be better than either alone. CHRONIC MYELOGENOUS LEUKEMIA (CML)-a stem cell disease with Philadelphia chromosome t(9;22) leading to fusion gene bcrabl , found in erythroblasts, megakaryocytes, granulocytes, monocytes, and most lymphocytes. ↓ LAP. Chronic phase → accelerated phase → blast crisis, 2/3 myeloid, 1/3 lymphoid · CHRONIC PHASE (5-6 years)-< 15% blasts, <20% basophils, and <30% blasts plus promyelocytes · ACCELERATED PHASE (6-9 months)-15-29% blasts, ≥20% basophils, ≥30% blasts + promyelocytes or platelets <100 × 10 3 /μL · BLAST CRISIS (3-6 months)-≥ 30% blasts or extramedullary involvement (chloroma for imatinib resistant disease. Allogeneic stem cell transplant is associated with 60-70% cure rate · ACCELERATED PHASE -imatinib mesylate 600-800 mg PO daily. Allogeneic stem cell transplant is associated with 30-45% cure rate · BLAST CRISIS -imatinib mesylate 800 mg PO daily, plasmapheresis. Allogeneic stem cell transplant is associated with 10-15% cure rate · IMATINIB -RESISTANT CML -dasitinib, nilotinib, and stem cell transplantation ESSENTIAL THROMBOCYTOSIS -aspirin, hydroxyurea, anagrelide MYELOFIBROSIS -hydroxyurea, ruxolitinib, splenectomy, interferon α , thalidomide

· HEMATOLOGICAL RESPONSE · COMPLETE RESPONSE -WBC <10 × 10 3 /μL with no immature granulocytes and <5% basophils, platelet <450 × 10 3 /μL, and nonpalpable spleen · PARTIAL RESPONSE -persistence of immature cells in peripheral blood, platelets >450 × 10 3 /μL but <50% of pre-treatment levels, or persistent splenomegaly but <50% of pre-treatment size · CYTOGENIC RESPONSE (FISH detection of the Philadelphia chromosome) · COMPLETE -0% Ph + cells · PARTIAL -1-35% Ph + cells · MAJOR -complete and partial cytogenetic response · MINOR -36-65% Ph + cells · MINIMAL -66-95% Ph + cells · MOLECULAR RESPONSE (bcr-abl transcript detection by RT-PCR) · COMPLETE -negative · MAJOR -bcr-abl to control gene ratio <0.1 (3 log decrease in bcr-abl transcript in peripheral blood) where HR = hematologic response, CHR = complete hematologic response, CGR = cytogenetic response, PCGR = partial cytogenetic response, CCGR = complete cytogenetic response, MMR = major molecular response, ACA = additional chromosomal abnormality MONITORING FOR CHRONIC MYELOGENOUS LEUKEMIA -bone marrow annually, quantitative PCR every 3 months (repeat test in 4 weeks if >0.5 log increase) IMATINIB RESISTANCEbcrabl mutations (T315I mutation confers tyrosine kinase inhibitor resistance), overexpression or amplification of bcrabl 

COMPLETE REMISSION -normal BM cellularity, <5% blasts in BM, none with leukemic phenotype or abnormal cytogenetics. Lumbar puncture after complete remission with induction chemotherapy, especially those with monoblastic phenotype. After induction, the remission rate in younger patients (<55 years) is 70-85%, but only 40-50% in older patients SCT -may opt for consolidation chemotherapy while identifying donor. SCT is a potentially curative therapy

MYELODYSPLASTIC SYNDROME (MDS)opposite of myeloproliferative disorders, decreased cell counts · SUBTYPES -refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with multilineage dysplasia, refractory anemia with multilineage dysplasia and ringed sideroblasts, refractory anemia with excess blasts (RAEB) 5-10% blasts, refractory anemia with excess blasts in transformation (RAEB-t) 10-19% blasts, MDS unclassified. RA and RARS are at low risk of transforming to AML (i.e. >20% blasts), while the rest are at high risk · DIAGNOSIS -peripheral blood smear (RBC with abnormal morphologic features, dysgranulopoiesis with Pelger-Huët deformity, nuclear atypia and hypogranulation, monocytosis), bone marrow biopsy · TREATMENTS -transfusions, erythropoietin/darbopoietin (for patients with serum EPO <500 ng/ ml and low transfusion requirement), treat infections early, 5-azacytidine, lenalidomide, decitabine, stem cell transplant (IPSS ≥1.5) ACUTE PROMYELOCYTIC LEUKEMIA M3, APL, PML · PATHOPHYSIOLOGY -associated with t(15;17) (q22;q21), which results in fusion of PML gene and retinoic acid receptor α gene. This gene product plays a key role in leukemogenesis.

Other combinations include t(11;17) with fusion of PLZF gene, t(5;17) with fusion of NPM gene, or t(11;17) with fusion of NuMA gene. Note that all except PLZF-RARA are susceptible to retinoic acid treatment · CLINICAL FEATURES -similar to AML. DIC commonly occurs in PML and should be monitored closely 

· TREATMENTS -induction with all-transretinoic acid (ATRA) plus idarubicin, then consolidation with anthracycline and cytarabine, and then maintenance with ATRA for 1 year. Retinoic acid exerts its effect via (1) degradation of PML-RAR protein, (2) transformation of PML-RAR from transcription repressor to activator, and (3) differentiation. Retinoic acid syndrome may occur with fever, respiratory distress, interstitial pulmonary infiltrates, pleural and pericardial effusion, episodic hypotension, acute renal failure, and weight gain. Arsenic trioxide can be used upfront (with ATRA) and for recurrent disease but is associated with QT prolongation and sudden death Acute Lymphoblastic Leukemia NEJM 2006 354:2 PATHOPHYSIOLOGY HISTOLOGIC TYPE · FAB L1 -small, uniform lymphoblasts with indistinct nucleoli · FAB L2 -larger, pleomorphic lymphoblasts with low nucleus to cytoplasm ratio and clear nucleoli · FAB L3 -large, pleomorphic lymphoblasts with basophilic cytoplasm, large nucleoli, vacuoles WHO CLASSIFICATION · PRECURSOR B CELL (L1, L2) · PRO -B ALL -resembles an early stage of B cell · PRE -B -CELL ALL -intracytoplasmic immunoglobulin · B -CELL ALL -express surface immunoglobulin · PRECURSOR T CELL (L1, L2) · BURKITT -LIKE ALL (L3) RISK FACTORS FOR ALL -age, previous chemotherapy or radiation, Down's syndrome

PANCYTOPENIA -weakness, fatigue, infections, gingival bleed, ecchymosis, petechiae, epistaxis, menorrhagia ORGAN INVOLVEMENT -lymphadenopathy, hepatomegaly, splenomegaly, bone pain, cranial nerve palsies, headaches NOTE : precursor B lymphoblastic lymphoma is associated with lymphadenopathy/extranodal involvement and < 25% blasts, while precursor T LBL is associated mediastinal mass and < 25% blasts

PROGNOSTIC FACTORS -while childhood ALL is curable in 85% of cases, adult ALL has a worse prognosis, with a 5-year survival of 35%. Factors associated with poorer survival include the following: · CLINICAL -lack of response to induction therapy (most important), old age, leukocyte count, CNS involvement · CYTOGENETICS -BCR-ABL fusion or t(9;22) (also known as the Philadelphia chromosome, in 20-50% of adults), MLL-AF4 fusion or t(4;11) (in 5-6% of adults), t(8;14), t(1;19), hypodiploidy (<45 chromosomes/cell), del (7), trisomy · FAVORABLE PROGNOSIS -hyperdiploidy, del(9), TELAML1 fusion or t(12;21) (in 10% of adults)

Larger Small Auer rods + -TdT -+ Myeloperoxidase + -

· LABS -CBCD, smear, lytes, urea, Cr, Ca, PO 4 , Mg, uric acid, albumin, urinalysis, LDH, INR, PTT, fibrinogen, flow cytometry of peripheral blood (immunophenotyping) · BONE MARROW BIOPSY -> 20% blast, flow cytometry for immunophenotyping, cytogenetic analysis (detection of BCR-ABL fusion and chromosomal abnormalities with pulsed-field gel electrophoresis and/or RT-PCR) · LUMBAR PUNCTURE -CSF for cytology · TISSUE BIOPSY -lymph node, skin, mediastinal mass SPECIAL · IMAGING -MUGA scan to evaluate cardiac function prior to anthracycline therapy · HLA TESTING -to assist in obtaining HLAmatched platelets if needed during treatment and to find HLA-matched allogeneic bone marrow

· HIGH RISK -any of age >60, t(9;22) or bcrabl , t(4;11), t(1;19); WBC >30 × 10 3 /μL in B-ALL or >100 × 10 3 /μL in T-ALL or pro-B ALL · STANDARD RISK -none of high-risk features RISK FACTORS FOR CNS RELAPSE -high-risk genetic features, T-ALL, large tumor burden, CSF positivity MANAGEMENT REMISSION INDUCTION THERAPY -combination chemotherapy with high-dose cyclophosphamide, prednisone, vincristine, ananthracycline ± asparaginase. Complete response 80-90%. Management of specific subgroups include · P H + ALL -add imatinib · L3 B -CELL ALL -treat like Burkitt's lymphoma · T -CELL ALL -treat with cyclophosphamidecontaining regimens CNS PROPHYLAXIS -to start after remission with intrathecal methotrexate with high-dose systemic methotrexate. Consider cranial radiation for patients at high risk of CNS relapse INTENSIFICATION/CONSOLIDATION THERAPY · STANDARD RISK -consolidation chemotherapy with various combinations of cyclophosphamide, 6-mercaptopurine, cytarabine, vincristine, and doxorubicin · HIGH RISK -SCT if donor available and eligible for transplant; otherwise, consolidation chemotherapy MAINTENANCE THERAPY -POMP (6-mercaptopurine daily, methotrexate weekly, vincristine and prednisone monthly) or dexamethasone for 2-3 years, except for patients who received allogeneic SCT (chlorambucil, cyclophosphamide, CVP) . Alemtuzumab (anti-CD52 antibody), bendamustine or ibrutininb (bruton's tyrosine kinase inhibitor) are useful for fludarabine-refractory disease. Indications for treatment include symptoms (weakness, painful lymphadenopathy, B symptoms, symptomatic splenomegaly), anemia (Hb <110 g/L [<11 g/dL]), thrombocytopenia (platelets <100 × 10 3 / μL), autoimmune hemolytic anemia/thrombocytopenia that failed steroids, progressive disease (increasing lymphocytosis with doubling time <6 months ± rapidly enlarging lymph nodes, spleen, and liver). If evidence of Richter's transformation, treat as aggressive lymphoma with R-CHOP NOTE -while traditionally SLL has been managed as a low-grade non-Hodgkin's lymphoma, it is identical to CLL and should be treated as such Two or more node regions on the same side of diaphragm. All nodal disease within the mediastinum is considered to be a single lymph node region and hilar involvement constitutes an additional site of involvement.

The number of anatomic regions should be indicated by a subscript (e.g. II 2 ) HISTOLOGIC TYPE · CLASSICAL H ODGKIN ' S LYMPHOMA (95%) -B-cell lymphoma characterized by the presence of Reed-Sternberg cells. CD15 and CD30 positive. Spreads in orderly fashion to contiguous nodal regions · NODULAR SCLEROSIS (70%)-more common in females, above diaphragm involvement (mediastinal mass). Three grades include lymphocyte predominant (G1), mixed (G2), and syncytial (G3) · MIXED CELLULARITY (20-25%)-more common in men. Tend to be EBV+. Retroperitoneal disease. Worse prognosis · LYMPHOCYTE RICH (5%)-more common in older males, peripheral lymph nodes. Excellent prognosis · LYMPHOCYTE DEPLETED (2%)-liver and marrow involvement with relative sparing of lymph nodes. 

EYE LYMPHOMA · PATHOPHYSIOLOGY -periorbital involvement (mostly MALT type) or intraocular involvement (usually DLBCL with more indolent course) · TREATMENTS -for periorbital MALT, involved field radiation if localized disease or CVP if widespread disease. For intraocular disease, steroids, and involved field radiation. Highdose methotrexate may be useful PRIMARY CNS LYMPHOMA · PATHOPHYSIOLOGY -usually multifocal but confined to CNS. May have leptomeningeal or intraocular involvement. Frequently aggressive B-cell lymphoma · CLINICAL FEATURES -focal neurological deficit, personality change, mild dementia, persistent headache · DIAGNOSIS -CT or MRI head, lumbar puncture, slit lamp examination. If CNS lymphoma in the differential, try to avoid giving steroids before biopsy. Always check HIV · TREATMENTS -high-dose corticosteroid with high-dose methotrexate is preferred. Whole brain radiation represents an alternative. Prognosis is 60% 2-year survival and 30% 5-year survival LEPTOMENINGEAL MENINGITIS · RISK FACTORS -aggressive lymphomas (lymphoblastic lymphoma, DLBCL, Burkitt's lymphoma, MCL), extranodal sites involvement (bone marrow, testicular, paranasal, retroperitoneal lymph nodes), any of the five IPI prognostic factors and tumor stage. Sezary syndrome is a systemic variant of mycosis fungoides with a triad of erythroderma, lymphadenopathy, and leukemia · CLINICAL FEATURES -localized patches or plaques evolving into nodules and diffuse exfoliative erythroderma associated with abnormal circulating cells. Poor prognostic factors include extensive cutaneous disease (erythroderma), nodal spread, and extracutaneous involvement (liver, spleen, lung, GI tract) · TREATMENTS -topical corticosteroids, topical nitrogen mustard, psoralen with UVA/UVB, bexarotene, radiation. Systemic treatments include CHOP, pentostatin, cladribine, fludarabine, IL-2, IFN α , alemtuzumab, liposomal doxorubicin SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA · PATHOPHYSIOLOGY -may be T-cell, B-cell, or null cell type. Uniform expression of CD4, CD30, clusterin and epithelial membrane antigen (EMA). Anaplastic lymphoma kinase (ALK) overexpression associated with t(2;5) is a key prognostic marker (ALK+ 65-90% 5-year survival vs. ALK-30-40% 5 year survival) · CLINICAL FEATURES -ALK+ cases usually present at younger age with early disease. ALK-cases usually present at older age with advanced stage, elevated LDH, B symptoms, and extranodal sites · TREATMENTS -CHOP-based regimens or brentuximab. Consider allogeneic stem cell transplant CASTLEMAN'S DISEASE · PATHOPHYSIOLOGY -lymphoid proliferation associated with POEMS syndrome, lymphomas (Hodgkin's, non-Hodgkin's), and Kaposi's sarcoma. HIV and HHV8 common in multicentric subtype · CLINICAL FEATURES -unicentric (isolated lymphadenopathy, benign, HHV8 negative). Multicentric (fever, night sweats, fatigue, lymphadenopathy, pulmonary infiltrates, frequently HHV8 and HIV positive) · TREATMENTS -unicentric (resection with high chance of cure, radiation, rituximab). Multicentric (rituximab, steroid, antivirals, anti-IL-6, CHOP) RISK FACTORS · PERSONAL -old age, black race · DISEASES -chronic polyclonal hypergammaglobulinemia · TREATMENT -radiation CLINICAL FEATURES SYMPTOMS · PANCYTOPENIA -weakness, fatigue, infections, gingival bleed, ecchymosis, epistaxis, menorrhagia · INCREASED POLYCLONAL PROTEIN -infections due to ↓ normal Ig, hyperviscosity syndrome · LYTIC BONE LESIONS -pain, fractures · HYPERCALCEMIA -weakness, nausea, abdominal pain, polyuria, altered mental status · NEUROLOGIC -peripheral neuropathy from amyloidosis, plasma cell infiltration of the meninges, cord compression, or radiculopathy from vertebral osteolytic lesions ± plasmacytoma · RENAL FAILURE · PRE -RENAL -N&V, renal vein thrombosis · RENAL -myeloma kidney (tubulointerstitial damage from increased light chain absorption at proximal tubule), plasma cell infiltration, Bence Jones/cast nephropathy, amyloidosis ( λ ), light-chain deposition disease ( κ ), hypercalcemia (nephrogenic DI), cryoglobulinemia, pyelonephritis, sepsis · POST -RENAL -renal stones (uric acid), neurogenic bladder · CONSTITUTIONAL -anorexia, fatigue, weight loss

· MULTIPLE MYELOMA · BONE MARROW PLASMA CELLS / PLASMACYTOMAno percent specified, but usually >10% · M -PROTEIN -in serum and/or urine, no concentration specified, but >30 

· LATE NON -HEMATOLOGIC -hypothyroidism, ste-

IgA <30 g/L [<3 g/dL], and urinary λ or κ chains <4 g/day. Median survival ~60 months · STAGE II (intermediate burden, 0.6-1.2 × 10 12 / m 2 )-between stages I and III. Median survival ~30 months · STAGE III (high tumor burden, >1.2 × 10 12 /m 2 )-any of Hb <85 g/L [<8.5 g/dL], Ca 2+ >2.6 mmol/L

Median survival 62 months · STAGE II -neither stage I nor III. Median survival 44 months · STAGE III -β2 microglobulin ≥5.5 mg/L. Median survival 29 months JCO

Febrile Neutropenia

of all evidence of disease · Nodal masses : if FDG-avid or PET positive prior to therapy, mass of any size permitted if PET negative. If variably FDG-avid or PET negative, regression to normal size on CT required · Liver and spleen : not palpable, nodules disappeared · Bone marrow : infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative PARTIAL REMISSION (PR)-regression of measurable disease and no new sites · Nodal masses : ≥50% decrease in sum of the product of the diameter (SPD) of up to 6 largest dominant masses; no increase in size of other nodes. If FDG-avid or PET positive prior to therapy, one or more PET positive at previously involved site; or if variably FDGavid or PET negative, regression on CT ≥50% decrease in SPD of nodules (for single nodule in greatest transverse diameter) · Liver and spleen : no increase in size · Bone marrow : irrelevant if positive prior to therapy; cell type should be specified STABLE DISEASE (SD)-failure to attain CR/PR or PD · Nodal masses : if FDG-avid or PET positive prior to therapy, PET positive at prior sites of disease and no new sites on CT or PET. If variably FDG-avid or PET negative, no change in size of previous lesions on CT RELAPSED DISEASE (RD) OR PROGRESSIVE DISEASE (PD)-any new lesion or increase by ≥50% of previously involved sites from nadir · Nodal masses : appearance of a new lesion(s) >1.5 cm in any axis, ≥50% increase in SPD of more than one node, or ≥50% increase in longest diameter of a previously identified node >1 cm in short axis. Lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy · Liver and spleen : >50% increase from nadir in the SPD of any previous lesions · Bone marrow : new or recurrent involvement JCO 2007 25:5 · CLINICAL FEATURES -jaw pain and numbness,  radicular pain, back pain, neck pain/rigidity,  confusion, cranial nerve deficits (especially II,  III, V, VI, VII) , focal weakness, sensory changes, headaches · DIAGNOSIS -lumbar puncture with positive cytology (sens 60% with single attempt, 3 attempts for increased yield), gadoliniumenhanced MRI showing enhancement and enlargement of one or more cranial nerves due to tumor infiltration · TREATMENTS -high-dose steroid (dexamethasone 12-20 mg PO/IV daily), radiation to the site of disease, intrathecal methotrexate, or cytarabine. Important to treat underlying systemic disease. Highly selected patients may benefit from highdose chemotherapy with stem cell transplantation with better outcomes. Median survival after CNS recurrence is 3 months LOCALI Z ED PARANASAL SINUS LYMPHOMA · PATHOPHYSIOLOGY -usually DLBCL type. May involve CNS if invade through the base of skull · CLINICAL FEATURES -local pain, rhinorrhea, nasal or upper airway obstruction, facial swelling, epistaxis, diplopia, visual loss · TREATMENTS -R-CHOP × 3 + involved field radiation + intrathecal chemotherapy × 6 MUCOSAASSOCIATED LYMPHOID TISSUE (MALT) · PATHOPHYSIOLOGY -extranodal marginal zone B-cell lymphomas that present with localized disease involving the GI tract, salivary glands, thyroid, orbit, conjunctiva, breast, and lung. Note that diffuse large cell lymphoma and mantle cell lymphoma also commonly involve GI mucosa · ASSOCIATIONS -H. pylori -associated chronic gastritis, Celiac disease, Crohn's disease, gastrointestinal nodular lymphoid hyperplasia · DIAGNOSIS -for gastric MALT, need to determine presence of H. pylori by biopsy (gastroscopy) ± urea breath test · TREATMENTS -for H. pylori -positive gastric MALT, triple therapy may be adequate. Need to confirm eradication of H. pylori . Follow closely with gastroscopy. If MALT persists for over 8-12 months, should consider single-agent chemotherapy (cyclophosphamide, chlorambucil) or involvedfield radiation. Partial gastrectomy may be needed for hemorrhage or perforation ACUTE LYMPHOBLASTIC LYMPHOMA · PATHOPHYSIOLOGY -continuum of presentation with acute lymphoblastic leukemia. Considered lymphoma if < 5% blasts in bone marrow; otherwise, considered leukemia · CLINICAL FEATURES -usually mediastinal mass in young males BURKITT'S LYMPHOMA · PATHOPHYSIOLOGY -t(8;14, 2;8, 8;22) leading to c-myc overexpression · CLINICAL FEATURES -usually advanced stage (80-90%). Abdominal mass, CNS, breast/ovarian involvement, and nodal sites but mediastinum usually spared TESTICULAR LYMPHOMA · PATHOPHYSIOLOGY -60% primary testicular lymphoma, 40% spread from other sites. Frequently DLBCL or immunoblastic subtype · CLINICAL FEATURES -painless testicular mass in older man. High risk for recurrence, particularly CNS relapse · DIAGNOSIS -scrotal US · TREATMENTS -unilateral orchiectomy + R-CHOP + involved field radiation to scrotum + intrathecal chemotherapy if stage III/IV disease POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (PTLD) · PATHOPHYSIOLOGY -mostly of host origin and usually EBV positive (LMP-1 oncogene). EBVnegative PTLD present later and are more aggressive than EBV-positive PTLD. Mostly B-cell non-Hodgkin's lymphoma and very rarely T-cell or NK cell lymphomas · RISK FACTORS -high degree of immunosuppression, pre-transplant EBV negativity. Risk highest in the first year, then reduces by 80% · CLINICAL FEATURES -clinical spectrum includes reactive plasmacytic hyperplasia (55%, infectious mononucleosis like illness with no malignant transformation), polymorphic B-cell hyperplasia (30%, polyclonal cytogenetic abnormalities, immunoglobulin gene rearrangements, and disruption of underlying tissue architecture), and B-or T-cell lymphomas (15%, monoclonal malignancy) · TREATMENTS -reduction in immunosuppression ( 

ALLOGENEIC TRANSPLANTATION (40%)stem cells from HLA-matched sibling donor (25%) or unrelated donor (75%). The main advantage is graft vs. leukemia effect (GVL), while the main disadvantage is graft vs. host effect (GVHD) AUTOLOGOUS TRANSPLANTATION (60%)stem cells from self. The main advantage is lesser toxicity compared to allogeneic transplant, while the main disadvantage is possible contamination of the graft with malignant cells HAPLOIDENTICAL TRANSPLANTATION (increasing use in adults)-stem cells from parent, child or sibling. Main advantage is the relative ease of identifying a donor, while the main disadvantage is graft rejection and GVHD DONOR SOURCEperipheral blood (10-20 L of blood, mobilization with GCSF, venipuncture, leukapheresis (up to 3 times for autologous stem cell transplant), faster engraftment, and improved overall survival (for autologous stem cell transplant and matched sibling allogeneic transplant), bone marrow , umbilical cord blood (expands supply of donors, although limited amount of stem cells in cord blood can affect engraftments and directs frequent use of "dual cord" transplantation; less GVHD with mismatches)

-dependent on age, underlying disease, donor availability, institutional preference. In general, allogeneic transplant is more suitable for younger, healthier adults as it is more toxic but potentially more effective than autologous transplant ALLOGENEIC -acute leukemia (50-70% cure if first remission, 10-30% cure if relapse), myelodysplastic syndrome (40-50% cure rate), chronic myeloid leukemia (50-70% cure if chronic phase, 10-30% cure if blast phase), chronic lymphocytic leukemia, indolent lymphoma, severe immunodeficiency syndromes, hemoglobinopathies

AUTOLOGOUS -progressive Hodgkin's lymphoma (60-70% cure if relapse, 40-50% cure if refractory disease), multiple myeloma, relapsed and progressive large cell lymphoma, relapsed germ cell cancer

HUMAN LEUKOCYTE ANTIGEN MOLECULESresponsible for displaying endogenous and exogenous peptides to T cells. Mismatch between host and donor HLA type could result in graft vs. host disease, graft failure, or death. Note that transplant is not affected by differences in ABO blood groups · HLA CLASS I -HLA-A, HLA-B, HLA-C · HLA CLASS II -HLA-DR, HLA-DQ, HLA-DP MATCHING PROCESS -ensure good match of HLA-A, HLA-B, HLA-C, DRB1, and DQB1. The chance of finding a sibling match is 1-0.75 n , where n = number of siblings. The chance of finding a matched unrelated donor is >60%, higher for Caucasians and lower for other races. Search for a match typically takes 3-4 months CONDITIONING -goal is to eradicate malignancy and suppress recipient's immune system to minimize rejection of donor's stem cells. Myeloablative regimens include cyclophosphamide plus total body irradiation (TBI) or high-dose busulfan. Reduced intensity regimens include fludarabine plus busulfan. Reduced intensity (also known as non-myeloablative or "mini" transplant) regimens use a milder conditioning regimen more tolerable for older patients (e.g. fludarabine plus cyclophosphamide, melphalan). Monitor toxicities closely during this time · HEMATOLOGIC -pancytopenia, febrile neutropenia · EARLY NON -HEMATOLOGIC -alopecia, N&V, oropharyngeal mucositis, diarrhea, sinusoidal obstruction syndrome (previously known as hepatic venoocclusive disease with tender hepatomegaly, jaundice and ascites), seizures, parotitis, pericarditis, cardiomyopathy, interstitial pneumonitis, hemorrhagic cystitis, rash rility or premature menopause, growth impairment, dry eyes or mouth, cataracts, osteopenia or osteoporosis · FERTILITY -infertility is almost certain in both men and women after TBI regimens, but not definite with non-TBI regimens. Consider oocyte/sperm/embryo cryopresevation · SECOND MALIGNANCIES -increased incidence of solid tumors (bone, oropharynx, connective tissue, CNS, thyroid, melanoma), myelodysplastic syndrome, acute myelogenous leukemia, and lymphoproliferative disorders. Highest risks in patients with TBI TRANSPLANTATION -infusion of stem cells over 30 min to 2 h ENGRAFTMENT -typically happens between days +10 and +20. Defined as ANC >0.5 × 10 3 /μL, with platelet and RBC engraftment following. GCSF may be used in non-leukemic patients to accelerate engraftment by up to 1 week. Patient is supported with blood products and antimicrobial prophylaxis (e.g. ciprofloxacin for Gram negatives, trimethoprim-sulfamethoxazole for PJP, acyclovir for HSV, fluconazole for fungal agents) until engraftment occurs. Failure to engraft (primary graft failure) and irreversible decline of blood counts (secondary graft failure) are serious complications (<5%). For non-myeloablative transplant, perform chimerism analysis and consider either donor leukocyte infusion (DLI) or reducing immunosuppression to improve disease control IMMUNE RECONSTITUTION -restoration of T-cell and B-cell immunity takes up to 12 months. Immunosuppressive treatment can usually be stopped within 1-3 years post-allogeneic transplant. Graft vs. host disease (GVHD) is a donor T-cell-mediated process. Overall transplantrelated mortality is approximately 20-25% GRAFT VS HOST DISEASE · ACUTE GVHD (<100 days)-occurs in 40%